A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 646-652

  Grosso, Dolores ^a   Gaballa, Sameh ^a,d   Alpdogan, Onder ^a   Carabasi, Matthew ^a   Filicko O'Hara, Joanne ^a   Kasner, Margaret ^a   Martinez Outschoorn, Ubaldo ^a   Wagner, John L ^a   O'Hara, William ^b   Rudolph, Shannon ^a   Chervoneva, Inna ^a   Colombe, Beth ^b   Farley, Patricia Cornett ^b   Flomenberg, Phyllis ^c   Pro, Barbara ^a   Sharma, Manish ^a   Shi, Wenyin ^a   Weiss, Mark ^a   Flomenberg, Neal ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Disease free survival; Donor availability; Haploidentical stem cell transplantation; Nonrelapse mortality; T cell dosing

Indexed keywords

CD135 ANTIGEN; CIDOFOVIR; CIPROFLOXACIN; DASATINIB; NUCLEOPHOSMIN; STEROID;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; AGED; ARTICLE; BK VIRUS; BLADDER IRRIGATION; BONE MARROW CELL; CLINICAL ARTICLE; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR SELECTION; DRUG WITHDRAWAL; ENCEPHALITIS; FEMALE; FEVER; GENE MUTATION; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL READMISSION; HUMAN; LUNG EMBOLISM; LYMPHOID CELL; MALE; MIDDLE AGED; MYELITIS; NATURAL KILLER CELL; NEPHROTOXICITY; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PUVA; RECURRENT DISEASE; SUBDURAL HEMATOMA; T LYMPHOCYTE; VOMITING; YOUNG ADULT; ALLOGRAFT; CANCER STAGING; CLINICAL TRIAL; DONOR; HEMATOLOGIC NEOPLASMS; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TISSUE DONORS;

EID: 84924225098     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.019     Document Type: Article

References (27)

1. Allan D.S., Takach S., Smith S., Goldman M. Impact of declining fertility rates in canada on donor options in blood and marrow transplantation. Biol Blood Marrow Transplant 2009, 15:1634-1637.
2. Babay E. Census: Big decline in nuclear family. November 26, 2013. Available at: Accessed: June 23, 2014. http://www.philly.com/philly/news/How_American_families_are_changing.html.
3. A portrait of stepfamilies. Pew Research Social and Demographic Trends. January 13, 2011. Available at: Accessed: May 15, 2014. http://www.pewsocialtrends.org/2011/01/13/a-portrait-of-stepfamilies.
4. Weisdorf D., Eapen M., Ruggeri A., et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord Analysis. Biol Blood Marrow Transplant 2014, 20:816-822.
5. Dew A., Collins D., Artz A., et al. Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant 2008, 14:938-941.
6. Gragert L., Eapen M., Williams E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry. NEngl J Med 2014, 371:339-348.
7. Grosso D., Flomenberg N. Atwo-step approach to allogeneic haploidentical hematopoietic stem cell transplantation. Semin Oncol 2012, 39:694-706.
8. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
9. Ringhoffer M., Wiesneth M., Harsdorf S., et al. CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. Br J Haematol 2004, 126:527-535.
10. Drobyski W.R., Klein J., Flomenberg N., et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002, 99:806-814.
11. Patriarca F., Luznik L., Medeot M., et al. Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014, 93:187-197.
12. Mayumi H., Good R.A. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. JExp Med 1989, 169:213-238.
13. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
14. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
15. Wagner J.L., Grosso D., Alpdogan O., et al. Engraftment and immune recovery (IR) in good risk patients undergoing hematopoietic stem cell transplantation (HSCT): comparison of two different approaches using cyclophosphamide (CY) for T-cell tolerization. Biol Blood Marrow Transplant 2014, 20:S254-S255.
16. Grosso D., Carabasi M., Filicko-O'Hara J., et al. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing. Blood 2011, 118:4732-4739.
17. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
18. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
19. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
20. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
21. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-956.
22. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013, 48:452-458.
23. Zhang X.-, Huang X.-, Liu K.-, et al. Idiopathic inflammatory demyelinating diseases of the central nervous system in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors and survival. Chin Med J 2013, 126:1096-1102.
24. Colvin G.A., Berz D., Ramanathan M., et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 2009, 15:421-431.
25. Guo M., Hu K.-, Liu G.-, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. JClin Oncol 2012, 30:4084-4090.
26. Craddock C. Pharmacological methods to reduce disease recurrence. Hematology Am Soc Hematol Educ Program 2013, 2013:63-69.
27. Zhang W.P., Yang D., Song X.M., et al. Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden. Biol Blood Marrow Transplant 2013, 19:653-660.